Dr. Jarushka Naidoo is a consultant medical oncologist at Beaumont Hospital in Dublin, Ireland. She is a clinical/translational investigator, specializing in immunotherapy for lung cancer, and immune-related toxicity. Dr. Naidoo’s research focus is on identifying novel biomarkers of response and toxicity to immunotherapy, and specifically for patients with lung cancer.
Dr. Naidoo’s project for the LCFA/IASLC/BMS Young Investigator grant in immuno-oncology, aims to identify whether a patient’s gut microbiome is implicated in their ability to derive benefit, or develop toxicity, from anti-PD-1/PD-L1 immunotherapy in lung cancer.